Clinical Insights and Guidance on New Evidence and the Expanding Treatment Options for Hemophilia

Join us for this live 1-hour, CME/CNE/CPE-certified workshop covering the latest advances in hemophilia treatment, including extended half-life and nonfactor therapies, emerging therapies aiming to restore the hemostatic balance and the latest advancements in gene therapy.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Advances in Factor Replacement Therapy

  • Goals of hemophilia treatment
  • Current data on the safety and efficacy of approved clotting factor replacement
  • Managing adherence to optimize therapeutic benefit
  • Future directions in factor replacement therapy

Improving Outcomes With Nonfactor Therapy for Hemophilia

  • FVIII mimetic antibodies
  • Investigational mimetic antibodies

Emerging Therapies Targeting Hemostatic Balance

  • Future directions in nonfactor therapy in hemophilia A and B
    • Rebalancers of hemostasis: anti-thrombin and inhibitors of coagulation inhibitors

Advancing Toward a Cure: Gene Therapy

  • Mechanisms of action and rationale for gene therapy in hemophilia
  • Ongoing clinical trials in gene therapy: hemophilia A & B
  • Implementation of gene therapy into clinical practice


Date / Time
Event Details


Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Children's Hospital
Harvard Medical School
Boston, Massachusetts

Guy A. Young, MD

Professor of Pediatrics
, Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Glaivy Batsuli, MD

Assistant Professor of Pediatrics
Pediatric Hematologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics
Emory University
Pediatric Hematologist
Pediatric Hematology and Oncology
Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta
Atlanta, Georgia

Allison P. Wheeler, MD

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in using novel therapeutic options for patients with hemophilia A and B.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with hemophilia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized hemophilia A and B prophylactic strategies that optimize adherence and clinical outcomes
  • Apply recent safety and efficacy data for newer factor replacement therapies in hemophilia A and B to clinical practice
  • Integrate the most recent data on currently available and emerging nonfactor prophylaxis into clinical practice for patients with hemophilia A and B
  • Discuss with patients the mechanisms of action, available data, along with benefits and potential risks of emerging gene therapies in hemophilia A and B care
  • Identify patients with hemophilia A or B who may be eligible for enrollment on a clinical trial


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-247-L01-P.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.